1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. News
  7. Summary
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

China stocks fall after hawkish Fed minutes; property, consumption drop

01/05/2022 | 11:56pm EDT

SHANGHAI, Jan 6 (Reuters) - China stocks fell on Thursday, tracking a global slump after Federal Reserve meeting minutes pointed to a faster-than-expected rise in U.S. interest rates, led by losses in real estate developers and consumer staples.

The CSI300 index fell 0.9%, to 4,826.06 points at the end of the morning session, while the Shanghai Composite Index lost 0.2%, to 3,589.50 points.

The Hang Seng index dropped 0.4%, to 22,824.60 points. The Hong Kong China Enterprises Index lost 0.4%, to 7,984.28.

** A "very tight" job market and unabated inflation might require the Federal Reserve to raise interest rates sooner than expected and begin reducing its overall asset holdings as a second brake on the economy, U.S. central bank policymakers said in their meeting last month.

** The more hawkish than expected views of U.S. central bank officials pushed U.S. Treasury yields higher, potentially draining liquidity from emerging markets.

** Refinitiv data showed outflows of more than 3.2 billion yuan through the Northbound legs of the Stock Connect programme ,, showing overseas investors were net sellers of A-shares on Thursday.

** Activity in China's services sector expanded at a faster pace in December amid higher demand and easing inflationary pressure but continuing small-scale COVID-19 outbreaks weighed on the outlook, a private sector survey showed.

** China will ensure stable economic growth in the first quarter of 2022, the government will implement greater tax and fee cuts for businesses and would provide targeted support for COVID-affected sectors, Premier Li Keqiang said on Wednesday.

** Real estate developers, consumer staples , transport stocks and media firms went down between 1.7% and 2.2%.

** Construction engineering shares surged 3.7%, while non ferrous metal gained 1.2%.

** In Hong Kong, the Hang Seng Tech Index lost 0.6%, while Alibaba Group and Meituan rebounded from previous session's slump and rose 3.6% and 0.5% respectively.

** Healthcare stocks dropped 2.6%, with WuXi Biologics down 4.2% to become the second biggest intraday decliner on the Hang Seng Index.

** The utilities subindex declined 2.7%.

(Reporting by Shanghai Newsroom)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ALIBABA GROUP HOLDING LIMITED -1.03% 86.79 Delayed Quote.-26.94%
AUSTRALIAN DOLLAR / US DOLLAR (AUD/USD) -0.13% 0.7032 Delayed Quote.-3.01%
BRITISH POUND / US DOLLAR (GBP/USD) 0.19% 1.24866 Delayed Quote.-7.89%
CANADIAN DOLLAR / US DOLLAR (CAD/USD) -0.17% 0.7783 Delayed Quote.-1.43%
EURO / US DOLLAR (EUR/USD) -0.18% 1.056 Delayed Quote.-6.97%
HANG SENG 2.96% 20717.24 Delayed Quote.-14.01%
INDIAN RUPEE / US DOLLAR (INR/USD) -0.59% 0.012844 Delayed Quote.-3.79%
MEITUAN INC. 4.53% 173 Delayed Quote.-23.25%
NEW ZEALAND DOLLAR / US DOLLAR (NZD/USD) 0.38% 0.64048 Delayed Quote.-6.67%
WUXI BIOLOGICS (CAYMAN) INC. 7.85% 56.3 Delayed Quote.-39.17%
All news about WUXI BIOLOGICS (CAYMAN) INC.
05/20Correction to Vir Biotechnology Shares Fall 9% Article
DJ
05/20Vir Biotechnology Shares Fall 9% After Terminating Agreement with WuXi Bio
DJ
05/20China stocks rise on higher-than-expected borrowing rate cut; foreign inflows surge
RE
05/11Hong Kong Stocks Rebound from Near Two-Month Low; Biotech Shares Rally
MT
04/27WuXi Biologics' 2021 ESG Report Reveals Company's Strong Commitment to Overall Sustaina..
PR
04/27WUXI BIOLOGICS CAYMAN : 2021 ESG Report
PU
04/14WUXI BIOLOGICS CAYMAN : Receives Bioprocessing Excellence Award from IMAPAC
PU
03/29UBS Adjusts Wuxi Biologics' Price Target to HK$110.67 From HK$142, Keeps at Buy
MT
03/24Nomura Adjusts WuXi Biologics' Price Target to HK$100.87 From HK$103.28, Keeps at Buy
MT
03/23Hong Kong Stocks Stage Back-to-Back Gains; Xiaomi, WuXi Bio Shares Jump on Upbeat Earni..
MT
More news
Analyst Recommendations on WUXI BIOLOGICS (CAYMAN) INC.
More recommendations
Financials
Sales 2022 14 998 M 2 241 M 2 241 M
Net income 2022 4 557 M 681 M 681 M
Net cash 2022 6 370 M 952 M 952 M
P/E ratio 2022 44,8x
Yield 2022 -
Capitalization 203 B 30 261 M 30 261 M
EV / Sales 2022 13,1x
EV / Sales 2023 9,39x
Nbr of Employees 9 864
Free-Float 84,2%
Chart WUXI BIOLOGICS (CAYMAN) INC.
Duration : Period :
WuXi Biologics (Cayman) Inc. Technical Analysis Chart | 2269 | KYG970081173 | MarketScreener
Technical analysis trends WUXI BIOLOGICS (CAYMAN) INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 26
Last Close Price 48,01 CNY
Average target price 91,42 CNY
Spread / Average Target 90,4%
EPS Revisions
Managers and Directors
Zhi Sheng Chen Director
Ming Tu Chief Financial Officer & Executive Vice President
Ge Li Non-Executive Chairman
Weichang Zhou Chief Technology Officer & Executive Director
William Robert Keller Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
WUXI BIOLOGICS (CAYMAN) INC.-39.17%30 261
CSL LIMITED-5.75%93 148
SAMSUNG BIOLOGICS CO.,LTD.-10.52%45 166
BIOGEN INC.-16.78%29 239
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-25.71%22 130
UCB-13.28%17 367